Maxim Group analyst Michael Okunewitch has maintained their bullish stance on LCTX stock, giving a Buy rating on January 3.Stay Ahead of the ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified ...